Latest Breaking News On - Clerval - Page 1 : comparemela.com

EyeDNA Therapeutics Announces Positive 24-month Data Presented at ARVO from Ongoing Phase I/II Trial of HORA-PDE6b Gene Therapy in Patients with Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b

eyeDNA Therapeutics to Present 2-year Follow-up Phase I/II Data on its Investigational Gene Therapy HORA-PDE6b for Retinitis Pigmentosa at the ARVO 2024 Annual Meeting

Coave Therapeutics to Present at Upcoming Conferences

Paris, France, March 27, 2024 – Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies, announces that its management will be attending the following upcoming investor and industry conferences: Cell & Gene Meeting on the Med – April 9-11 ; Rome, ItalyCompany Presentation by CEO Rodolphe Clerval on April 10 at 13.45 CET LSX World Congress – April 29-30 ; London, UKCEO Rodolphe Clerval attending and available for investor meetings BioEquity Europe –

Coave Therapeutics Receives Grant from the ALS Association to Advance its CTx-TFEB Program as a Potential Treatment for All Forms of ALS

Coave Therapeutics to Present at Upcoming Conferences

Paris, France, September 28, 2023 – Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies for CNS (Central Nervous System) and eye diseases, announces that CEO Rodolphe Clerval will be presenting to investors and peers at the following Investor and Industry conferences: Chardan’s 7th Annual Genetic Medicines Conference – October 2-3 New York City, NY, USAPresenting on October 2 at 11:30 EDT Cell & Gene Meeting on the Mesa – October 10-12 Carlsbad,